Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

158.58 +2.57 (+1.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 387,954
Open 155.90
Bid (Size) 140.00 (1)
Ask (Size) 165.00 (2)
Prev. Close 156.01
Today's Range 153.96 - 159.28
52wk Range 117.64 - 186.22
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea... 
Via Benzinga
Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with... 
Via Benzinga

Performance

YTD
+20.78%
+20.78%
1 Month
+7.48%
+7.48%
3 Month
-0.20%
-0.20%
6 Month
+24.47%
+24.47%
1 Year
-12.47%
-12.47%

More News

Read More
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity
Via Benzinga
Switzerland Removes Medical Marijuana Access Limitations As Demand Rises
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
Via Benzinga
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate
Via Benzinga
Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL
Via Benzinga
4 Analysts Have This to Say About Jazz Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Via Benzinga
Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research
Via Benzinga
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization?
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Via Benzinga
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals
Via Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Via FinancialNewsMedia
Exposures COVID-19
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
Via Investor's Business Daily
Jazz Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval?
Via Benzinga
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
Via Benzinga
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY
Via Benzinga
Jazz Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End
Via Benzinga
Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.